Has Faisal Chaudhry received payments from drug or device companies?

Yes. Drug and device makers reported $8,546 in general payments to Faisal Chaudhry across 177 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Faisal Chaudhry did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Faisal Chaudhry come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Faisal Chaudhry

Psychiatry · Brooklyn, NYNPI 1366559668

Payments from drug & device makers

$8,546in general payments, 2019–2025

Across 177 payments — averaging $48.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$3K
Otsuka America Pharmaceutical, Inc.$2K
Teva Pharmaceuticals USA, Inc.$1K
Neurocrine Biosciences, Inc.$656
Alkermes, Inc.$439
Indivior Inc.$145
plus $429 from 5 others

What the payments were for

Food & beverage$8,541100%
Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	78	$3,344
Otsuka America Pharmaceutical, Inc.	60	$2,368
Teva Pharmaceuticals USA, Inc.	10	$1,165
Neurocrine Biosciences, Inc.	7	$656
Alkermes, Inc.	6	$439
Indivior Inc.	3	$145
Genentech USA, Inc.	8	$140
AbbVie	1	$111
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$104
Lundbeck LLC	2	$53
AstraZeneca	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,546 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Invega TrinzaPaliperidone Palmitate	13	$110,672
Invega SustennaPaliperidone Palmitate	35	$78,743
Risperdal ConstaRisperidone Microspheres	25	$20,977
Haloperidol Decanoate	55	$1,671
Paliperidone ErPaliperidone	13	$865
Clozapine	11	$567
Benztropine Mesylate	49	$263
Mirtazapine	15	$190
Risperidone	24	$145
Olanzapine	23	$107
Haloperidol	13	$94
Sertraline Hcl	29	$87
Quetiapine Fumarate	11	$69
Trazodone Hcl	14	$65
Lorazepam	12	$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta	$3,344	$210,39373 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Brooklyn

Inna Yuryev-GolgerBrooklyn$3M
Zinoviy BenzarBrooklyn$505K
Nikhil PalekarBrooklyn$481K
Mark OwensBrooklyn$286K
Elyssa BarronWhite Plains$12.8M
Mark DibuonoStaten Island$11.9M
Ronald BrennerHempstead$11.5M
Anton PorsteinssonRochester$7.6M
Michael LiebowitzNew York$7.1M
Leslie CitromePomona$5.7M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →